Larson Financial Group’s KalVista Pharmaceuticals KALV Stock Holding History

Larson Financial Group’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,657	Closed	-$33.4K	–	3868
2026 Q1	$33.4K	Buy	1,657 +934	+129%	+$15.1K	﹤0.01%	1572
2025 Q4	$11.7K	Buy	723 +33	+5%	+$437	﹤0.01%	2026
2025 Q3	$8.4K	Buy	690 +524	+316%	+$7.24K	﹤0.01%	2105
2025 Q2	$1.88K	Buy	166 +22	+15%	+$269	﹤0.01%	2427
2025 Q1	$1.66K	Buy	+144	New	+$1.47K	﹤0.01%	2226

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Larson Financial Group's KALV Position: Q2 2026 in Review

Larson Financial Group sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 1,657 shares — an estimated $33.4K sold.

Larson Financial Group first reported a position in KALV in Q1 2025 and held it in 5 quarters. The position peaked at $33.4K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Larson Financial Group reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Larson Financial Group sold 1,657 KalVista Pharmaceuticals shares in Q2 2026, an estimated $33.4K.
Larson Financial Group first reported a position in KalVista Pharmaceuticals in Q1 2025 and held it in 5 quarters.
Larson Financial Group's KalVista Pharmaceuticals position peaked at $33.4K in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.